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Cowden Syndrome is a rare multiple hamartoma syndrome that
confers an increased risk of breast, thyroid, endometrial, and potentially
colon cancer in affected individuals with lifetime risks estimated at
5–10% for endometrial cancer, 25–50% for breast cancer, 3–10% for
thyroid cancer and 13% for colon cancer (Daley et al., 2011). Cowden
Syndrome has an incidence of 1 in 200,000 (NCCN guidelines, reference
102–3), and is deﬁned at the molecular level by a mutation in
the phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-
speciﬁcity protein phosphatase (PTEN) gene located at chromosome
10q23.3. PTEN is an intracellular signaling molecule involved in cellular
proliferation and apoptosis (Daley et al., 2011). The clinical diagnosis
of Cowden Syndrome can be difﬁcult and is based on several clinical
criteria. A personal history of Bannayan–Riley–Ruvalcaba Syndrome
(BRRS), adult Lhermitte–Duclos disease (LDD), autism with macroce-
phaly, or ≥2 trichelemomma would warrant testing. Major criteria
include breast cancer, mucocutaneous lesions, macrocephaly, endome-
trial cancer, non-medullary thyroid cancer, or multiple GI hamartomas
or ganglioneuromas. Minor criteria include other thyroid lesions,
mental retardation, autism spectrum disorder, single GI hamartomas
or ganglioneuromas, ﬁbrocystic breast disease, lipomas, ﬁbromas, renaldu (J.M. Edwards), scm6h@virginia.edu
er CC BY-NC-ND license .major criteria (only need two if macrocephaly is one of them), ≥Two
major plus one minor criteria, one major plus 3 minor criteria, or
≥Four minor criteria (NCCN guidelines) (Nelen et al., 1996).
Atypical polypoid adenomyoma (APA) is an uncommon lesion of
the uterus generally seen in premenopausal women. APA is deﬁned
pathologically by a proliferation of irregular endometrial glands
with squamous metaplasia and morule formation embedded within
a prominent cellular smooth-muscle stroma (Eng, 2000). APA usually
presents with abnormal uterine bleeding in conjunction with a polyp-
oid mass in the lower uterine segment (Mazur, 1981). These lesions
are most commonly benign, but have been reported to co-exist with
endometrioid endometrial carcinoma; however APA has not been
previously reported as a manifestation of Cowden Syndrome in the
English literature (Sugiyama et al., 1998).
The objective of this paperwas to report a case of Cowden Syndrome
with associated endometrial carcinoma and APA and to discuss the diag-
nosis, screening and risk reduction strategies for clinicians taking care of
women with this signiﬁcant gynecologic and breast cancer syndrome.Case
A 33-year-old nulliparous woman with a past medical history sig-
niﬁcant for obesity, type 2 diabetes mellitus, hypertension, hyperlip-
idemia, and multinodular thyroid disease presented with abnormal
vaginal bleeding and a large vaginal mass. Past gynecologic history
is signiﬁcant for menarche at age 10 with irregular periods, which
had been previously managed with oral contraceptives. Four years
prior to this presentation, a Pap test found atypical squamous cells
(HPV negative) and endometrial cells but she had never had any
endometrial evaluation.
She has a family history signiﬁcant for Cowden Syndrome by way
of positive molecular diagnostic testing in her father and she met clin-
ical diagnosis criteria as she had three major criteria (macrocephaly,
biopsy proven trichilemmoma and multiple GI hamartomas and
ganglioneuromas), and several minor criteria (thyroid disease and
lipomas). The patient had not received molecular diagnostic testing;
however, she had undergone genetic counseling as part of her routine
care but had never had been compliant with any additional screening
or care recommendations based on the Cowden diagnosis.
Fig. 1. Large lower uterine segment mass.T2 sagittal pelvic MRI with contrast demon-
strating a large lower uterine segment mass, as indicated by arrow, prolapsing through
the cervix and into the vagina.
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ian syndrome; however examination by referring physician revealed
a large vaginal mass. Subsequent MRI of the pelvis revealed a large
heterogeneous loosely packed uterine mass extending from the
dome of the uterus to the introitus. The mass was seen to expand
the endometrial and vaginal canals without evidence of myometrial
or vaginal wall invasion (Fig. 1).
She was taken to the operating room and transvaginal excision
of mass and uterine curettage were performed. A 5.0 cm mass was
prolapsing through the cervix with an endocervical vs. lower uterine
segment origin and consisted of pink-brown soft tissue. Cut surfaces
were white to tan and whorled in appearance. Microscopic view of
hematoxylin and eosin stained slides demonstrated a complex mix-
ture of smooth muscle and endometrial glands best described as
atypical polypoid adenomyoma. Additionally, there was an endome-
trial tissue with a high degree of architectural complexity including
cribriform and conﬂuent glands consistent with endometrioid adeno-
carcinoma, FIGO Grade 1 with squamous metaplasia.
After discussion at Tumor Board and with the patient, she elected
to undergo a robotic-assisted total laparoscopic hysterectomy. Frozen
section revealed a grade one tumor with no evidence of myometrialFig. 2. Focus of cancer in APA.H&E stain at 40× magniﬁcation of surgical specimen
demonstrates a focus of FIGO grade 1 endometrioid adenocarcinoma arising in the
APA. Sections show tightly packed/crowded endometrial glands with cribriforming.invasion. Her ovaries were left in situ due to her desire to preserve
ovarian function and possible future fertility. Her post-operative
course was uneventful and she remains disease free.
Final pathologic analysis of the surgical specimen indicated a focal
area of endometrioid adenocarcinoma, FIGO grade I, limited to the
endometrium (Fig. 2). This well-differentiated lesion arose within
the atypical polypoid adenomyoma and exhibited several areas of
squamous differentiation.
Comment
The diagnosis of Cowden Syndrome can be difﬁcult to establish
partly due to the rarity of the diagnosis and the unfamiliarity of
many physicians with the syndrome characteristics. This patient
met the criteria for genetic testing for Cowden as she had three
major criteria (biopsy proven trichilemmoma, endometrial cancer,
multiple GI hamartomas and ganglioneuromas). In an individual
with a relative diagnosed with Cowden Syndrome, only one major
criterion or two minor criteria are necessary to justify testing. If
there is a known familial PTEN mutation, then testing should be con-
sidered for the speciﬁc mutation. If there is no known mutation, then
the affected family member with the highest likelihood of mutation
should be tested. In this case, the patient's father had a known muta-
tion. She declined testing. Therefore screening and counseling were
provided as if she was positive.
Recommended cancer screening for women with Cowden Syn-
drome includes breast, colon, skin and thyroid evaluation (Table 1).
NCCN recommends self-breast exam training and education starting
at age 18 with a clinical breast exam annually at age 25 or
5–10 years before earliest known family breast cancer. Additionally
annual mammography and breast MRI screening should begin at
age 30–35 or 5–10 years before the earliest known family breast can-
cer. Endometrial cancer screening is based primarily on education.
Patients should be educated about symptoms and there should be a
low threshold for endometrial sampling. In addition to female speciﬁc
screening exams, all patients with Cowden's syndrome should have
comprehensive annual exam and dermatologic exam. They should
also have a baseline thyroid ultrasound at age 18 with consideration
for annual exam thereafter. Finally, colonoscopy at age 35 then
every 5–10 years based on ﬁndings should be performed due to the
association with early onset colon cancer (about 13%) as well as the
numerous polyps. In addition to screening, patients should be coun-
seled regarding risk reduction methods including mastectomy and
hysterectomy; this should be discussed with patients on a case-by-
case basis and patients should be counseled on degree of protection,
extent of cancer risk, and reconstruction options.
Progression of atypical polypoid adenomyoma to endometrial
adenocarcinoma is not generally seen as a risk in clinical practice.
Exploration of the literature reveals that the molecular pathogenesisTable 1
Cowden Syndrome screening recommendations.
Cancer Screening recommendation
Breast Annual clinical breast exam — starting at 25 or 5–10 years before
earliest known breast cancer in family.
Annual mammography and breast MRI — starting at 30–35 or
5–10 years before earliest known breast cancer in family.
Discuss risk-reducing mastectomy including degree of protection,
cancer risk, and reconstructive options.
Thyroid Baseline thyroid ultrasound at age 18 with consideration for
annual ultrasounds.
Endometrial Patient education regarding symptoms along with screening
methods and effectiveness.
Discuss risk-reducing hysterectomy including degree of protection,
cancer risk, and fertility options.
Colon Consider colonoscopy at 35 then every 5–10 years based on ﬁndings.
Skin Annual dermatologic exam
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its progression to endometrial cancer. Inactivation of PTEN can cause
activation of the PI3K–Akt pathway causing increased cellular levels
of β-catenin (Longacre et al., 1996). β-catenin has been shown to
activate gene expression leading to increased cellular proliferation
and decreased apoptosis (Stambolic et al., 1998). Molecular analysis
of APA specimens demonstrates accumulation of β-catenin in both
the cytoplasm and nucleus without β-catenin gene (CTNNB-1) muta-
tion. Additionally, CTNNB-1 mutation leading to increased cellular
β-catenin is commonly seen in the transition from endometrial
hyperplasia to endometrioid endometrial carcinoma (Peifer, 1997).
Mutation in PTEN and its effects on down-stream pathways are also
frequently seen in EEC (Ota et al., 2003). Therefore, a genetic back-
ground of Cowden Syndrome may have contributed to the develop-
ment of APA and its progression to cancer in this patient.
APA does not have a standard treatment regimen in clinical prac-
tice. Patients who desire preserved fertility are often treated with
polypectomy or dilation and curettage. Successful pregnancies have
been documented after these procedures (Bussaglia et al., 2000).
When fertility is no longer desired, simple hysterectomy serves as a
deﬁnitive treatment. In a pre-menopausal woman with no other indi-
cation for salpingo-oophorectomy, the ovaries can be left in situ in
order to prevent surgical menopause.
Development of endometrioid endometrial carcinoma in APA
warrants deﬁnitive treatment. The most appropriate treatment is hys-
terectomywith staging. In the setting of Cowden Syndrome, full patho-
logic evaluation of all APA specimens in search of an occult carcinoma is
especially important because of the possible molecular contribution to
progression and the implications on clinical treatment. Even though
this patient demonstrated malignant transformation, no surveillance
above that required for any patient with Cowden Syndrome is required.
Limited knowledge of both endometrioid endometrial carcinoma
in Cowden Syndrome and APA indicates that further studies arenecessary in order to elucidate the molecular pathogenesis of these
conditions. The unusual progression of APA to cancer in this genetic
background highlights the role of both PTEN and its downstream
activators on carcinogenesis, especially endometrial carcinogenesis.
Additionally, clinical screening, prevention, and treatment guidelines
need to be developed based on both the molecular and clinical knowl-
edge of these conditions.
Conﬂict of interest statement
None of the aforementioned authors have any conﬂicts of interest to declare in relation
to this publication.
References
Bussaglia, E., Del Rio, E., Matias-Guiu, X., Prat, J., 2000. PTEN mutations in endometrial
carcinomas: a molecular and clinicopathologic analysis of 38 cases. Hum. Pathol.
31, 312–317.
Daley, M.B., Allen, J., Axilbund, J.D., Buys, S., Crawford, B., Farrell, C.D., et al., 2011. Genetic/
Familial High-risk Assessment: Breast and Ovarian. NCCN Guidelines Version 1.
Eng, C., 2000. Will the real Cowden syndrome please stand up: revised diagnostic criteria.
J. Med. Genet. 37, 828–830.
Longacre, T.A., Chung, M.H., Rouse, R.V., Hendrickson, M.R., 1996. Atypical polypoid
adenomyoﬁbroma (atypical polypoid adenomyomas) of the uterus. Am. J. Surg.
Pathol. 20, 1–20.
Mazur, M.T., 1981. Atypical polypoid adenomyoma of the endometrium. Am. J. Surg.
Pathol. 5, 473–482.
Nelen, M.R., Padberg, G.W., Peeters, E.A.J., Lin, A.Y., van den Helm, B., Frants, R.R., et al.,
1996. Localization of the gene for Cowden disease to 10q22–23. Nat. Genet. 13,
114–116.
Ota, S., Catasus, L., Matias-Guiu, X., Bussaglia, E., Lagarda, H., Pons, et al., 2003. Molecular
pathology of atypical polypoid adenomyoma of the uterus. Hum. Pathol. 34,
784–788.
Peifer, M., 1997. β-catenin as oncogene. Science 275, 1752–1753.
Stambolic, V., Suzuki, A., de la Pompa, J.L., Brothers, G.M., Mirtsos, C., Sasaki, T., et al.,
1998. Negative regulation of PKB/Akt-dependent cell survival by the tumor
suppressor PTEN. Cell 95, 29–39.
Sugiyama, T., Ota, S., Nishida, T., Okura, N., Tanabe, K., Yakushiji, M., 1998. Two cases of
endometrial adenocarcinoma arising from atypical polypoid adenomyoma. Gynecol.
Oncol. 71, 141–144.
